Repligen Corp.
http://www.repligen.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Repligen Corp.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Deal Watch: Gilead Acquires Xilio’s IL-12 Activating Candidate
Plus deals involving Avalo/AlmataBio, AbbVie/Parvus, NovaBay/Eyenovia, Bayer/Aignostics, Merck & Co./Pearl, tech transfer agreements and deals in brief.
Gilead’s Trispecific Alliance With Merus Continues Its Push In Novel Cancer Tech
Deal Snapshot: Gilead adds to its pipeline of multispecific antibodies for cancer, while Merus gets a first partner for its trispecific platform.
Gilead Gets License To Compugen’s Potential First-In-Class IL-18 Target For Cancer
The company will pay $60m for rights to the preclinical asset COM503, which could be a new type of immuno-oncology drug.
Company Information
- Industry
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
-
- Atoll GmBH
- Avitide, Inc.
- Bio-Flex Solutions LLC
- C Technologies, Inc.
- Newton T&M Corp.
- Novozymes Biopharma Sweden AB
- TangenX Technology Corporation
- Polymem S.A.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice